share_log

Cantor Fitzgerald Downgrades IBio to Neutral, Lowers Price Target to $0.17

Cantor Fitzgerald Downgrades IBio to Neutral, Lowers Price Target to $0.17

坎托·菲茨杰拉德将iBio评级下调至中性,将目标股价下调至0.17美元
Benzinga Real-time News ·  2022/10/07 05:21

Cantor Fitzgerald analyst Kristen Kluska downgrades iBio (AMEX:IBIO) from Overweight to Neutral and lowers the price target from $2.5 to $0.17.

坎托·菲茨杰拉德分析师克里斯汀·克鲁斯卡将iBio(AMEX: IBIO)的评级从增持下调至中性,并将目标股价从2.5美元下调至0.17美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发